Kinase Inhibition in Multiple Myeloma: Current Scenario and Clinical Perspectives

Kinase Inhibition in Multiple Myeloma: Current Scenario and Clinical Perspectives

Multiple myeloma (MM) is a blood cell neoplasm characterized by excessive production of malignant monoclonal plasma cells (activated B lymphocytes) by the bone marrow, which end up synthesizing antibodies or antibody fragments, called M proteins, in excess. The accumulation of this production, both...

Full description

Bibliographic Details
Main Authors: Igor Valentim Barreto, Caio Bezerra Machado, Davi Benevides Almeida, Flávia Melo Cunha de Pinho Pessoa, Renan Brito Gadelha, Laudreísa da Costa Pantoja, Deivide de Sousa Oliveira, Rodrigo Monteiro Ribeiro, Germison Silva Lopes, Manoel Odorico de Moraes Filho, Maria Elisabete Amaral de Moraes, André Salim Khayat, Edivaldo Herculano Correa de Oliveira, Caroline Aquino Moreira-Nunes
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Pharmaceutics
Subjects:
multiple myeloma
tyrosine kinase
treatment
ibrutinib
Online Access:https://www.mdpi.com/1999-4923/14/9/1784

Similar Items

Similar Items